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Myelodysplastic syndromes (MDS) have long been considered hematopoietic cell-autonomous 
disorders in which disease initiation and progression is exclusively driven by hematopoietic cell 
intrinsic genetic events. Recent experimental findings have challenged this view, implicating 
mesenchymal elements in the bone marrow microenvironment in disease pathogenesis. 
Specifically, genetic perturbation of mesenchymal cells has the ability to induce MDS and acute 
myeloid leukemia (AML), establishing an experimental concept of ‘niche-induced’ 
oncogenesis.(1, 2) Alternatively, primary alterations in hematopoietic cells have the ability to alter 
mesenchymal niche components such that niche cells facilitate disease propagation in the 
context of xenograft transplantation.(3) Together, these observations challenge the view that 
ineffective hematopoiesis and leukemic progression is exclusively driven by hematopoietic-cell 
autonomous events in human MDS. Translation of experimental findings to human disease is 
complicated by a lack of insight in the molecular wiring of primary, non-expanded, mesenchymal 
cells in MDS. Insights into the biology of mesenchymal elements in human MDS, and other 
hematopoietic disorders, thus far, have been derived from studies investigating ex vivo 
expanded mesenchymal cells derived from the diseased bone marrow. The hierarchic, biologic 
and molecular relationship between these ex vivo expanded cells and their in situ counterparts, 
however, has remained largely unknown. Here, we describe massive parallel transcriptome 
sequencing of prospectively isolated mesenchymal elements from human low risk MDS (LR-
MDS), revealing a common molecular signature, distinct from both normal and ex vivo 
expanded cells, characterized by cellular stress and upregulation of genes encoding 
inflammation-associated secreted factors with established inhibitory effects on hematopoiesis. 
 
Mesenchymal cells were prospectively FACS-sorted from bone marrow aspirates of LR-MDS 
patients (n=12, Supplementary Table S1) and normal controls (n=10) using previously 
established markers of primary bone marrow mesenchymal cells (Figure 1A).(4) The frequency 
of CD45-/7AAD-/CD235a-/CD31-/CD271+/CD105+ mesenchymal cells in LR-MDS was not 
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significantly different from normal bone marrow (Figure 1B) (0.019%±0.0086% vs. 
0.022%±0.0066% of mononuclear cells (MNCs), p=0.819 by unpaired student t-test), and these 
cells comprised a small subset of CD45-/7AAD-/CD235a- ‘niche’ cells (10.41%±4.086% vs. 
12.30%±5.052, p=0.771) with the major constituent being CD31+ endothelial cells 
(43.80%±7.243% vs. 38.28%±9.424%, p=0.816).  
 
RNA was extracted from highly purified mesenchymal elements and cDNA synthesis was 
performed using the SMARTer Ultra Low RNA kit for Illumina Sequencing (Clonetech) 
(Supplementary Methods). Quality of RNA-sequencing data was shown to be similar for normal 
and LR-MDS derived samples using various quality parameters including the number of aligned 
bases, base composition, coverage coefficient and full-length transcript coverage (from 5’ end to 
3’ end) reflecting no systematic 5’-end or 3’-end bias (Supplementary Figure S1). The 
mesenchymal identity of CD45-/7AAD-/CD235a-/CD31-/CD271+/CD105+ cells was confirmed 
molecularly by whole transcriptome analysis demonstrating significant abundance of transcripts 
encoding defining membrane proteins (Figure 1C), established markers of mesenchymal stem 
cells (Figure 1D)(4, 5), essential ‘niche’ factors governing the behavior of hematopoietic stem and 
progenitor cells (HSPCs) (Figure 1E) and osteolineage markers (Figure 1F) compared to 
endothelial cells. Collectively, the findings demonstrate the feasibility of prospective isolation 
and molecular characterization of highly purified primary mesenchymal elements in LR-MDS by 
massive parallel transcriptome sequencing.  
 
Principle component analysis (PCA) of all transcriptomes demonstrated uniform clustering of 
normal mesenchymal cells, implying transcriptional homogeneity (Figure 2A). Strikingly, distinct 
and more heterogeneous clustering of mesenchymal transcriptomes was found in LR-MDS 
revealing that these cells are transcriptionally distinct from their normal counterparts. Gene set 
enrichment analysis (GSEA) was subsequently performed to define the molecular networks 
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underlying the distinct transcriptional landscape of LR-MDS. Gene sets associated with 
inflammatory response and cellular stress were remarkably enriched in LR-MDS (Figure 2B-C; 
Supplementary Table S2). Cellular stress was reflected by a reduced capacity of the CD271+ 
mesenchymal population in LR-MDS to form colonies (Figure 2D) with morphologic features 
reminiscent of cellular senescence (Figure 2E), as described earlier for expanded stromal cells 
in LR-MDS.(6, 7) Distinct hierarchical clustering and the signatures of cellular stress were not 
age-dependent, as these signatures remained statistically significant when examined in an age-
matched sub-cohort of patients and controls (Supplementary Figure S2). Together, the data 
indicate that mesenchymal cells in LR-MDS are molecularly and functionally distinct from their 
normal counterparts, characterized by cellular stress, reflected by a reduced, ex vivo, capacity 
to form fibroblast colonies. 
 
Thus far, molecular and biologic insights into the role of mesenchymal cells in the pathogenesis 
of human MDS have been derived from studies using ex vivo expanded, plastic adherent 
stromal cells. The molecular relationship between these expanded cells and their in situ 
mesenchymal counterparts has remained largely unknown. Elucidation of the transcriptome of 
mesenchymal elements in the MDS marrow allows us to compare our transcriptional data to 
sequencing data obtained from expanded cells in an age-matched cohort of LR-MDS published 
earlier (Supplementary Figure S3).(3)  
 
Comparison of FDR-significant differentially expressed transcripts between the two datasets 
demonstrated limited overlap (Figure 2F), suggesting distinct molecular wiring between the two 
mesenchymal cell sources. To obtain insight into the biologic processes underlying differential 
gene expression, GO (gene ontologies) term analysis was performed focusing on cellular 
biologic processes. To correct for potential experimental differences affecting FPKM values, we 
normalized expression of all genes in LR-MDS to the expression of the controls in the 
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respective data sets as detailed in the Supplementary Methods section. Normalized expression 
was subsequently used to perform GO term analysis and GSEA, comparing sorted to expanded 
cells.  
 
25 GO terms were significantly (FDR < 0.25) enriched in primary CD271+ mesenchymal cells 
(while no signatures were enriched in the ex vivo expanded mesenchymal cells), many of which 
(8/25) reflected response to external stimuli, chemokine activity and immune regulation (Figure 
2G). Transcript abundance analysis in CD271+ cells in comparison to their normal counterparts 
indeed revealed significant upregulation of numerous cytokines (Supplementary Table S3), 
including a large number of inflammatory factors, such as IL6 and IL8, and a wide variety of 
factors previously demonstrated to be negative regulators of hematopoiesis, in particular 
erythropoiesis and B-lymphopoiesis, cell lineages that are typically affected in LR-MDS 
(Supplementary Table S3).  
 
To obtain insight into the molecular pathways underlying the biologic processes identified, 
transcriptional network analysis (GSEA) was performed. This  identified 504 gene sets that were 
significantly (FDR < 0.25) enriched in primary sorted LR-MDS stromal cells, whereas 16 
signatures were enriched in expanded LR-MDS stromal cells. Again, gene signatures related to 
inflammation and cellular stress were enriched in CD271+ cells with a remarkable abundance of 
signatures related to EGF, TGFß and TNF signaling (Supplementary Figure S4, Table S4).  
 
Collectively, the data comprise, to our knowledge, the first comprehensive transcriptional 
network analysis of highly purified mesenchymal elements directly isolated from the marrow in 
human hematopoietic disease. They support the view that these cells are intricately implicated 
in MDS disease pathogenesis, stressing the relevance of considering the tissue context in 
generating a comprehensive understanding of the disease. The data further support the notion 
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that inflammatory signaling is an important pathophysiologic factor in LR-MDS and implicate the 
mesenchyme in this process. Finally, the data complement findings derived from ex vivo stromal 
cells in this disease revealing preferential overexpression of inflammatory pathways and 
secreted factors in FACS-purified CD271+ cells. This likely reflects active cross-talk with other 
cellular elements within the inflammatory bone marrow environment in LR-MDS(8), eliciting or 
maintaining these transcriptional programs, which may not be  fully appreciated in ex vivo 
cultures.  
The finding that secretory programs implicated in negative regulation of hematopoiesis are 
activated in CD271+ cells may be of particular relevance given their close anatomical proximity 
with CD34+ cells(9), potentially harboring the MDS initiating population.(10) The data warrant 
future investigations unraveling the signaling between cellular elements in the MDS marrow 
driving these secretory programs. We anticipate that elucidation of the transcriptome of highly 
purified mesenchymal elements in MDS will thus be a valuable resource to the community, 
instructing the validation and discovery of novel pathophysiologic factors and putative 
therapeutic targets.(11)  
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Figure legends 
 
Figure 1. Prospective isolation and molecular characterization of mesenchymal cells in LR-MDS. 
(A) Gating strategy to identify and isolate 7AAD-/CD45-/CD235a-/CD271+/CD105+ mesenchymal cells. (B) 
Frequency of mesenchymal cells in normal and MDS samples. (C-F) Transcriptional validation of the 
mesenchymal identity of 7AAD-/CD45-/CD235a-/CD271+/CD105+ cells, revealing differential expression in 
comparison to endothelial subsets of (C) defining cell surface markers (CD271, CD105, CD31), (D) 
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known mesenchymal markers (CD73, CD90, CD146), (E) established hematopoiesis-supporting 
cytokines (CXCL12, ANGPT1, KITL) and (F) bone lineage markers (BGLAP, RUNX2, SPP1 and ALPL).  
 
FPKM: fragments per kilobase of exon per million fragments mapped. CD73 (NT5E: ecto-5'-
nucleotidase); CD90 (THY1: Thy-1 T-Cell Antigen); CD146 (MCAM: melanoma cell adhesion molecule); 
CXCL12 (stromal cell-derived factor 1); ANGPT1 (angiopoietin 1); KITL (KIT ligand); BGLAP 
(osteocalcin); RUNX2 (runt-related transcription factor 2); SPP1 (osteopontin); ALPL (alkaline 
phosphatase, liver/bone/kidney). Figure C to figure F: Normal samples (n=10); MDS samples (n=12). 
Black bar: CD271+ mesenchymal cells; white bar: CD31+ endothelial cells. ** FDR < .01; *** FDR < .001. 
 
Figure 2. Mesenchymal cells in LR-MDS display a distinct molecular signature characterized by 
cellular stress and inflammation. (A) Principle component analysis (PCA) on the transcriptomes of 
normal and LR-MDS mesenchymal cells. Patient numbers in Figure 2A refer to LR-MDS patient IDs 
(Table S1). (B) Example of GSEA plot revealing inflammatory response in the mesenchymal cells from 
LR-MDS. (C) Representative GSEA plot demonstrating deregulation of the gene set associated with 
cellular stress in response to UV in LR-MDS mesenchymal cells. Gene set size, NES and FDR value of 
each gene set is listed. GSEA: gene sets enrichment analysis. NES: normalized enrichment score. FDR: 
false discovery rate. (D) Number of CFU-F colonies formed by normal (n=3) or LR-MDS (n=3) CD271+ 
mesenchymal cells. (E) Representative images of cell clusters and colonies formed by mesenchymal cells 
from healthy control (left panel) and LR-MDS patients (right panel). (F) Comparison of significantly 
differentially expressed genes in FACS-purified CD271+ versus culture-expanded mesenchymal cells in 
LR-MDS. The total number of differentially regulated transcripts in each data set is indicated and the 
overlapping differentially regulated genes in the two datasets are listed. (G) Biologic processes 
significantly enriched (FDR < 0.25) in FACS-purified CD271+  LR-MDS mesenchymal cells in comparison 
to  expanded stromal cells defined by GO term analysis.  ** P < .01 
 
 
 
 
  
Figure 1 
 
 
CHEN et al  STROMAL INFLAMMATION IN MDS 
1 
 
Figure 2 
 
